Notch ligand Delta-like 4 blockade attenuates atherosclerosis and metabolic disorders
Swirski, Filip K.
Novobrantseva, Tatiana I.
Gorgun, Cem Z.
Aster, Jon C.
Hotamisligil, Gökhan S.
MetadataShow full item record
CitationFukuda, D., E. Aikawa, F. K. Swirski, T. I. Novobrantseva, V. Kotelianski, C. Z. Gorgun, A. Chudnovskiy, et al. 2012. “Notch Ligand Delta-like 4 Blockade Attenuates Atherosclerosis and Metabolic Disorders.” Proceedings of the National Academy of Sciences 109 (27): E1868–77. https://doi.org/10.1073/pnas.1116889109.
AbstractAtherosclerosis and insulin resistance are major components of the cardiometabolic syndrome, a global health threat associated with a systemic inflammatory state. Notch signaling regulates tissue development and participates in innate and adaptive immunity in adults. The role of Notch signaling in cardiometabolic inflammation, however, remains obscure. We noted that a high-fat, high-cholesterol diet increased expression of the Notch ligand Delta-like 4 (Dll4) in atheromata and fat tissue in LDL-receptor-deficient mice. Blockade of Dll4-Notch signaling using neutralizing anti-Dll4 antibody attenuated the development of atherosclerosis, diminished plaque calcification, improved insulin resistance, and decreased fat accumulation. These changes were accompanied by decreased macrophage accumulation, diminished expression of monocyte chemoattractant protein-1 (MCP-1), and lower levels of nuclear factor-kappa B (NF-kappa B) activation. In vitro cell culture experiments revealed that Dll4-mediated Notch signaling increases MCP-1 expression via NF-kappa B, providing a possible mechanism for in vivo effects. Furthermore, Dll4 skewed macrophages toward a proinflammatory phenotype ("M1"). These results suggest that Dll4-Notch signaling plays a central role in the shared mechanism for the pathogenesis of cardiometabolic disorders.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:41384347
- HMS Scholarly Articles